RIPE-KG · Version 1.1.0 · Resource

ripekg:registry-evidence/RIPEA62FEC5B159F50CEC

https://w3id.org/ripe/ripe-kg/registry-evidence/RIPEA62FEC5B159F50CEC

Subject	Predicate	Object
`ripekg:evaluation/RIPEA62FEC5B159F50CEC`	`prov:used`	`ripekg:registry-evidence/RIPEA62FEC5B159F50CEC`
`ripekg:registry-evidence/RIPEA62FEC5B159F50CEC`	`rdf:type`	`rdfs:Resource`
`ripekg:registry-evidence/RIPEA62FEC5B159F50CEC`	`rdf:type`	`owl:Thing`
`ripekg:registry-evidence/RIPEA62FEC5B159F50CEC`	`rdf:type`	`ripe:IntegrityAssessmentEvidence`Integrity assessment evidence
`ripekg:registry-evidence/RIPEA62FEC5B159F50CEC`	`rdf:type`	`ripe:RegistryEvidence`Registry evidence
`ripekg:registry-evidence/RIPEA62FEC5B159F50CEC`	`rdf:type`	`tido:Evidence`
`ripekg:registry-evidence/RIPEA62FEC5B159F50CEC`	`prov:wasAttributedTo`	`ripekg:source/clinicaltrials-gov`ClinicalTrials.gov
`ripekg:registry-evidence/RIPEA62FEC5B159F50CEC`	`prov:wasGeneratedBy`	`ripekg:evidence-aggregation/RIPEA62FEC5B159F50CEC`
`ripekg:registry-evidence/RIPEA62FEC5B159F50CEC`	`prov:wasMemberOf`	`ripekg:research-integrity-assessment/RIPEA62FEC5B159F50CEC`
`ripekg:registry-evidence/RIPEA62FEC5B159F50CEC`	`ripe:concerns`	`ripekg:work/10.1016%2Fj.eururo.2013.04.001`OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial
`ripekg:registry-evidence/RIPEA62FEC5B159F50CEC`	`ripe:isProspective`	true
`ripekg:registry-evidence/RIPEA62FEC5B159F50CEC`	`ripe:registrationAssessmentRationale`	Comparison performed at month level. Registration: 2009-05, LLM Recruitment Start: 2009-10. Deemed prospective at month level.
`ripekg:registry-evidence/RIPEA62FEC5B159F50CEC`	`ripe:registrationDate`	29-05-2009
`ripekg:registry-evidence/RIPEA62FEC5B159F50CEC`	`ripe:registrationId`	NCT00910520
`ripekg:registry-evidence/RIPEA62FEC5B159F50CEC`	`ripe:registrationLink`	https://clinicaltrials.gov/study/NCT00910520
`ripekg:registry-evidence/RIPEA62FEC5B159F50CEC`	`ripe:registryName`	ClinicalTrials.gov
`ripekg:registry-evidence/RIPEA62FEC5B159F50CEC`	`tido:supports`	`ripekg:integrity-assessment-hypothesis/RIPEA62FEC5B159F50CEC-human-2-2`
`ripekg:registry-evidence/RIPEA62FEC5B159F50CEC`	`tido:supports`	`ripekg:integrity-assessment-hypothesis/RIPEA62FEC5B159F50CEC-inspectai-2-2`